Amgen Inc. $AMGN Shares Purchased by Sumitomo Mitsui Financial Group Inc.

Sumitomo Mitsui Financial Group Inc. boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 7.8% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 75,779 shares of the medical research company’s stock after purchasing an additional 5,457 shares during the quarter. Sumitomo Mitsui Financial Group Inc.’s holdings in Amgen were worth $21,385,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in AMGN. Banco Santander S.A. increased its holdings in Amgen by 5.8% during the 3rd quarter. Banco Santander S.A. now owns 20,053 shares of the medical research company’s stock valued at $5,659,000 after acquiring an additional 1,102 shares in the last quarter. Mill Creek Capital Advisors LLC increased its stake in shares of Amgen by 9.7% during the 3rd quarter. Mill Creek Capital Advisors LLC now owns 4,108 shares of the medical research company’s stock worth $1,159,000 after purchasing an additional 364 shares in the last quarter. Lansing Street Advisors raised its position in shares of Amgen by 1.4% during the 3rd quarter. Lansing Street Advisors now owns 3,937 shares of the medical research company’s stock worth $1,111,000 after purchasing an additional 54 shares during the last quarter. Diversify Wealth Management LLC raised its position in shares of Amgen by 7.0% during the 3rd quarter. Diversify Wealth Management LLC now owns 12,968 shares of the medical research company’s stock worth $3,843,000 after purchasing an additional 852 shares during the last quarter. Finally, Integrated Advisors Network LLC lifted its stake in Amgen by 5.6% in the 3rd quarter. Integrated Advisors Network LLC now owns 12,622 shares of the medical research company’s stock valued at $3,562,000 after buying an additional 667 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen hit an all-time intraday high, reflecting strong investor demand and momentum that likely supported upward price pressure earlier in the session. Amgen stock hits all-time high
• Positive Sentiment: Amgen is featured in dividend-stock roundup articles, which can attract long-term income-focused buyers and support demand for shares given its yield and payout profile. Got $10,000? Put It in These Dividend Stocks Now
• Neutral Sentiment: Commentary pieces note Amgen has outpaced the Dow over the past year, providing a positive performance backdrop — but analysts remain cautious, suggesting upside may be tempered by valuation and execution risks. Is Amgen Stock Outperforming the Dow?
• Neutral Sentiment: Legislative risk: S.3847 (Stop Corporate Inversions Act of 2026) was flagged as potentially relevant to multinationals including AMGN; the bill would tighten rules around inversion tax treatment — a longer-term policy item to monitor but not an immediate earnings driver. Stop Corporate Inversions Act of 2026
• Neutral Sentiment: Reported spikes in short interest appear in the feed but show zero shares/NaN in the figures — this looks like a data or reporting error rather than a meaningful change in positioning; still worth checking official exchange short-interest releases for confirmation.
• Negative Sentiment: A small institutional holder (Bradley Foster & Sargent) trimmed its position (~1,336 shares), a minor selling signal that may slightly contribute to sell-side flow but is not materially large versus Amgen’s market cap and average volume. Bradley Foster & Sargent Inc. CT Sells 1,336 Shares

Amgen Price Performance

Shares of Amgen stock opened at $379.33 on Friday. The business’s fifty day moving average price is $347.68 and its 200 day moving average price is $318.76. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $387.49. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The stock has a market capitalization of $204.48 billion, a P/E ratio of 26.66, a PEG ratio of 3.81 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same period in the prior year, the firm posted $5.31 earnings per share. The firm’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.7%. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio is 70.84%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AMGN. Argus raised their price target on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Citigroup lifted their price objective on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research note on Thursday, February 5th. The Goldman Sachs Group upped their price objective on shares of Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. Finally, Morgan Stanley lifted their target price on shares of Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and an average price target of $351.76.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.